Substrate and drug binding sites in LeuT

Current Opinion in Structural Biology

Volumn 20, Issue 4, 2010, Pages 415-422

  Nyola, Ajeeta ^a   Karpowich, Nathan K ^a   Zhen, Juan ^a   Marden, Jennifer ^a   Reith, Maarten E ^a   Wang, Da Neng ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSPORTER; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; CITALOPRAM; CLOMIPRAMINE; COCAINE; DESIPRAMINE; DOPAMINE TRANSPORTER; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LEUCINE TRANSPORTER; NEUROTRANSMITTER; NISOXETINE; NORADRENALIN TRANSPORTER; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN; UNCLASSIFIED DRUG;

COMPLEX FORMATION; CRYSTAL STRUCTURE; DEPRESSION; DRUG BINDING SITE; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; ENZYME SUBSTRATE COMPLEX; HUMAN; MAMMAL; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION;

AMINO ACID TRANSPORT SYSTEMS; ANIMALS; BINDING SITES; HUMANS; LEUCINE; PHARMACEUTICAL PREPARATIONS; PLASMA MEMBRANE NEUROTRANSMITTER TRANSPORT PROTEINS; SUBSTRATE SPECIFICITY;

MAMMALIA;

EID: 77955981124     PISSN: 0959440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sbi.2010.05.007     Document Type: Review

References (51)

1. Rudnick G. Mechanisms of biogenic amine neurotransmitter transporters. Neurotransmitter Transporters: Structure, Function, and Regulation 2002, 25-52. Humana Press. edn 2. M.E.A. Reith (Ed.).
2. Torres G.E., Gainetdinov R.R., Caron M.G. Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 2003, 4:13-25.
3. Kanner B.I., Zomot E. Sodium-coupled neurotransmitter transporters. Chem Rev 2008, 108:1654-1668.
4. Androutsellis-Theotokis A., Goldberg N.R., Ueda K., Beppu T., Beckman M.L., Das S., Javitch J.A., Rudnick G. Characterization of a functional bacterial homologue of sodium-dependent neurotransmitter transporters. J Biol Chem 2003, 278:12703-12709.
5. --dependent neurotransmitter transporters. Nature 2005, 437:215-223.
6. --dependent transporters. Proc Natl Acad Sci USA 2007, 104:12761-12766.
7. Zomot E., Bendahan A., Quick M., Zhao Y., Javitch J.A., Kanner B.I. Mechanism of chloride interaction with neurotransmitter:sodium symporters. Nature 2007, 449:726-730.
8. + and substrate is triggered by substrate in a second binding site. Mol Cell 2008, 30:667-677.
9. Zhou Z., Zhen J., Karpowich N.K., Goetz R.M., Law C.J., Reith M.E., Wang D.N. LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. Science 2007, 317:1390-1393.
10. Singh S.K., Yamashita A., Gouaux E. Antidepressant binding site in a bacterial homologue of neurotransmitter transporters. Nature 2007, 448:952-956.
11. Celik L., Schiott B., Tajkhorshid E. Substrate binding and formation of an occluded state in the leucine transporter. Biophys J 2008, 94:1600-1612.
12. Tang L., Bai L., Wang W.H., Jiang T. Crystal structure of the carnitine transporter and insights into the antiport mechanism. Nat Struct Mol Biol 2010, 17:492-496.
13. Karpowich N.K., Wang D.N. Structural biology. Symmetric transporters for asymmetric transport. Science 2008, 321:781-782.
14. Schmitt K.C., Mamidyala S., Biswas S., Dutta A.K., Reith M.E. Bivalent phenethylamines as novel dopamine transporter inhibitors: evidence for multiple substrate-binding sites in a single transporter. J Neurochem 2010, 112:1605-1618.
15. Nielsen S., Pedersen C.M., Hansen S.G., Petersen M.D., Sinning S., Wiborg O., Jensen H.H., Bols M. An extended study of dimeric phenyl tropanes. Bioorg Med Chem 2009, 17:4900-4909.
16. Talvenheimo J., Nelson P.J., Rudnick G. Mechanism of imipramine inhibition of platelet 5-hydroxytryptamine transport. J Biol Chem 1979, 254:4631-4635.
17. Zhou Z., Zhen J., Karpowich N.K., Law C.J., Reith M.E., Wang D.N. Antidepressants specificity of serotonin transporter suggested by three LeuT-SSRI complex structures. Nat Struct Mol Biol 2009, 16:652-657.
18. Roubert C., Cox P.J., Bruss M., Hamon M., Bonisch H., Giros B. Determination of residues in the norepinephrine transporter that are critical for tricyclic antidepressant affinity. J Biol Chem 2001, 276:8254-8260.
19. Barker E.L., Blakely R.D. Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter. Mol Pharmacol 1996, 50:957-965.
20. Henry L.K., Field J.R., Adkins E.M., Parnas M.L., Vaughan R.A., Zou M.F., Newman A.H., Blakely R.D. Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants. J Biol Chem 2006, 281:2012-2023.
21. Walline C.C., Nichols D.E., Carroll F.I., Barker E.L. Comparative molecular field analysis using selectivity fields reveals residues in the third transmembrane helix of the serotonin transporter associated with substrate and antagonist recognition. J Pharmacol Exp Ther 2008, 325:791-800.
22. Sinning S., Musgaard M., Jensen M., Severinsen K., Celik L., Koldso H., Meyer T., Bols M., Jensen H.H., Schiott B., et al. Binding and orientation of tricyclic antidepressants within the central substrate site of the human serotonin transporter. J Biol Chem 2010, 285:8363-8374.
23. Plenge P., Wiborg O. High- and low-affinity binding of S-citalopram to the human serotonin transporter mutated at 20 putatively important amino acid positions. Neurosci Lett 2005, 383:203-208.
24. Cherubino F., Miszner A., Renna M.D., Sangaletti R., Giovannardi S., Bossi E. GABA transporter lysine 448: a key residue for tricyclic antidepressants interaction. Cell Mol Life Sci 2009, 66:3797-3808.
25. Andersen J., Taboureau O., Hansen K.B., Olsen L., Egebjerg J., Stromgaard K., Kristensen A.S. Location of the antidepressant binding site in the serotonin transporter: importance of Ser-438 in recognition of citalopram and tricyclic antidepressants. J Biol Chem 2009, 284:10276-10284.
26. Andersen J., Olsen L., Hansen K.B., Taboureau O., Jorgensen F.S., Jorgensen A.M., Bang-Andersen B., Egebjerg J., Stromgaard K., Kristensen A.S. Mutational mapping and modeling of the binding site for (S)-citalopram in the human serotonin transporter. J Biol Chem 2010, 285:2051-2063.
27. Plenge P., Mellerup E.T. Antidepressive drugs can change the affinity of [3H]imipramine and [3H]paroxetine binding to platelet and neuronal membranes. Eur J Pharmacol 1985, 119:1-8.
28. Jorgensen A.M., Topiol S. Driving forces for ligand migration in the leucine transporter. Chem Biol Drug Des 2008, 72:265-272.
29. Klingenberg M. Ligand-protein interaction in biomembrane carriers. The induced transition fit of transport catalysis. Biochemistry 2005, 44:8563-8570.
30. Tatsumi M., Groshan K., Blakely R.D., Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997, 340:249-258.
31. Eshleman A.J., Carmolli M., Cumbay M., Martens C.R., Neve K.A., Janowsky A. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J Pharmacol Exp Ther 1999, 289:877-885.
32. Pinder R.M., Wieringa J.H. Third-generation antidepressants. Med Res Rev 1993, 13:259-325.
33. Roman D.L., Walline C.C., Rodriguez G.J., Barker E.L. Interactions of antidepressants with the serotonin transporter: a contemporary molecular analysis. Eur J Pharmacol 2003, 479:53-63.
34. Welch W.M., Kraska A.R., Sarges R., Koe B.K. Nontricyclic antidepressant agents derived from cis- and trans-1-amino-4-aryltetralins. J Med Chem 1984, 27:1508-1515.
35. Wong D.T., Bymaster F.P., Engleman E.A. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 1995, 57:411-441.
36. Wong D.T., Bymaster F.P. Development of antidepressant drugs. Fluoxetine (Prozac) and other selective serotonin uptake inhibitors. Adv Exp Med Biol 1995, 363:77-95.
37. Iversen L. Antidepressants. Burger's Medical Chemistry and Drug Discovery 2003, vol 6:483-524. Wiley. edn 6.
38. Eildal J.N., Andersen J., Kristensen A.S., Jorgensen A.M., Bang-Andersen B., Jorgensen M., Stromgaard K. From the selective serotonin transporter inhibitor citalopram to the selective norepinephrine transporter inhibitor talopram: synthesis and structure-activity relationship studies. J Med Chem 2008, 51:3045-3048.
39. Rupp A., Kovar K.A., Beuerle G., Ruf C., Folkers G. A new pharmophoric model for 5-HT reuptake-inhibitors: differentiation of amphetamine analogues. Pharm Acta Helv 1994, 68:235-244.
40. Butler S.G., Meegan M.J. Recent developments in the design of anti-depressive therapies: targeting the serotonin transporter. Curr Med Chem 2008, 15:1737-1761.
41. Heal D.J., Aspley S., Prow M.R., Jackson H.C., Martin K.F., Cheetham S.C. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int J Obes Relat Metab Disord 1998, 22(Suppl. 1):S18-S28.
42. Sanchez C., Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999, 19:467-489.
43. Pearce R.K., Smith L.A., Jackson M.J., Banerji T., Scheel-Kruger J., Jenner P. The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets. Mov Disord 2002, 17:877-886.
44. Lehr T., Staab A., Tillmann C., Trommeshauser D., Raschig A., Schaefer H.G., Kloft C. Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease. Br J Clin Pharmacol 2007, 64:36-48.
45. Rothman R.B., Partilla J.S., Baumann M.H., Dersch C.M., Carroll F.I., Rice K.C. Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse. Synapse 2000, 35:222-227.
46. Skolnick P., Popik P., Janowsky A., Beer B., Lippa A.S. Antidepressant-like actions of DOV 21,947: a " triple" reuptake inhibitor. Eur J Pharmacol 2003, 461:99-104.
47. Singh S.K., Piscitelli C.L., Yamashita A., Gouaux E. A competitive inhibitor traps LeuT in an open-to-out conformation. Science 2008, 322:1655-1660.
48. Ritz M.C., Lamb R.J., Goldberg S.R., Kuhar M.J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987, 237:1219-1223.
49. Wu Q., Reith M.E., Kuhar M.J., Carroll F.I., Garris P.A. Preferential increases in nucleus accumbens dopamine after systemic cocaine administration are caused by unique characteristics of dopamine neurotransmission. J Neurosci 2001, 21:6338-6347.
50. Beuming T., Kniazeff J., Bergmann M.L., Shi L., Gracia L., Raniszewska K., Newman A.H., Javitch J.A., Weinstein H., Gether U., et al. The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci 2008, 11:780-789.
51. DeLano W.L. The PyMOL User's Manual 2002, DeLano Scientific, San Carlos, CA.